众生药业：关于控股子公司一类创新药昂拉地韦项目两项III期临床试验获得顶线分析数据结果的公告

Group 1 - The core announcement is that Zhongsheng Pharmaceutical's subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., has reported positive topline data from Phase III clinical trials for two innovative drugs: Angladewe Granules for treating uncomplicated influenza A in children aged 2 to 11 and Angladewe Tablets for adolescents aged 12 to 17 [1] - The preliminary results indicate that Angladewe Granules and Angladewe Tablets demonstrated effective therapeutic outcomes and good safety profiles in their respective age groups, achieving the expected objectives of the trials [1]